Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide and Capecitabine in Metastatic Breast Cancer
NCT00193102Phase 2Terminated
- Sponsor
- SCRI Development Innovations
- Start
- Apr 2001
- Primary completion
- Feb 2005
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of thalidomide in breast cancer, sponsored by SCRI Development Innovations. Primary endpoint: Overall Response Rate at 18 months. Started Apr 2001; status: terminated.
02
Drugs
thalidomide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00193102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00193102.